Clinical trials
Refractory Solid Tumors clinical trials
Below are recruiting refractory solid tumors clinical trials, each written for real people, not researchers. We’re tracking 355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06368921RecruitingPhase 1
Study of M1 virus injection for advanced solid tumors
This trial tests a virus called M1 (VRT106) that may be able to infect and destroy cancer cells. It's given by injection directly into a tumor, and is for people whose advanced solid tumors haven't responded to other treatments.
Guangzhou, GuangdongAges 18–75 - NCT06210815RecruitingPhase 1
Testing a new drug HLX42 for advanced solid tumors
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
Guangdong, GuangzhouAges 18–75 - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT06320405RecruitingPhase 1/Phase 2
Combination therapy for advanced solid tumors
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Portland, OregonAges 18 years+ - NCT06302621RecruitingPhase 1
Pemigatinib plus afatinib for advanced solid tumors with FGFR changes
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
Boston, MassachusettsAges 18 years+ - NCT06241898RecruitingPhase 1
First study of a new drug for advanced solid tumors
This study tests a new drug (BB-1709) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it's safe and how well it works.
Beijing, Beijing MunicipalityAges 18–78 - NCT06234098RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT06234423RecruitingPhase 1
A study of CUSP06 for advanced solid tumors
This study tests a new drug called CUSP06 for people with advanced solid tumors, especially ovarian cancer that has stopped responding to platinum chemotherapy. It may help if standard treatments no longer work.
Denver, ColoradoAges 18 years+ - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06150885RecruitingPhase 1/Phase 2
An immune cell therapy for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR gamma-delta T cells) for advanced solid tumors that have not responded to standard treatments. The therapy uses donor cells that are specially trained to find and attack cancer cells.
Taichung, Non-USAges 18 years+ - NCT06136884RecruitingPhase 1
Study of AO-252 for advanced solid tumors with or without brain metastases
This trial tests an experimental oral pill (AO-252) that targets a protein called TACC3 in advanced solid tumors, including those that have spread to the brain. It is for people whose cancer has a specific genetic change (TP53 mutation) or who have prostate cancer, and who have already tried other treatments.
Detroit, MichiganAges 18 years+ - NCT06132503RecruitingPhase 1
Testing LP-284 for advanced lymphomas and solid tumors
This trial tests an experimental drug called LP-284 in people with certain advanced lymphomas or solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against these cancers.
West Valley City, UtahAges 18 years+ - NCT06046742RecruitingPhase 1
IV M1-c6v1 for advanced solid tumors
This trial tests an experimental drug called M1-c6v1 given through an IV for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective.
Kashiwa-shi, ChibaAges 18 years+ - NCT06006273RecruitingPhase 1
Testing a new drug combo for children with returning solid tumors
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
Houston, TexasAges 1–25 - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Phoenix, ArizonaAges 18 years+ - NCT06014502RecruitingPhase 1
Study of IMGS-001 for advanced solid tumors that returned after treatment
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
Gilbert, ArizonaAges 18 years+ - NCT05985161RecruitingPhase 2
Selinexor for wilms tumor and other solid tumors
This trial tests a drug called selinexor for children and young adults with certain types of solid tumors (like Wilms tumor, rhabdoid tumors, MPNST, or others with specific genetic changes) that have come back or not responded to standard treatment. Participants take selinexor pills to see if it can shrink or control their cancer.
Los Angeles, CaliforniaAges 1 year+ - NCT05958121RecruitingPhase 1/Phase 2
IMA402 immune therapy for advanced solid tumors
This trial tests an immune system treatment (IMA402) that is meant to help the body recognize and fight advanced solid tumors. It may be an option if your cancer has come back or did not respond to standard treatments, and if your overall health and tumor measurements meet study requirements.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT05907980RecruitingPhase 1
ROSE12 alone and with other drugs for advanced solid tumors
This trial tests a new drug called ROSE12, given alone or with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapies. The study aims to see if ROSE12 is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05892718RecruitingPhase 1
Testing an immune drug for hard-to-treat cancers
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Port Saint Lucie, FloridaAges 18 years+ - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+
Hear when a new Refractory Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory solid tumors?
- Yes. Clin2 currently lists 355 recruiting refractory solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.